The University of Texas MD Anderson Cancer Center

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billion Full year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70 SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025. "We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year," said Jim Davis, Chairman, CEO, and President. "Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers' needs and to form strategic collaborations supporting growth. Our 2026 guidance reflects our continued confidence in our business strengths and market fundamentals." Key 2025 Highlights: Serving Clinicians and Health Systems Began to deploy our largest Co-Lab Solutions implementation to date for Corewell Health, a leading health system in Michigan. Also finalized a laboratory-services joint venture with Corewell Health that includes plans to open a state-of-the-art laboratory in southeast Michigan in 2027. Scaled lab testing to deliver services for more than 200,000 patients at Fresenius Medical Care's dialysis centers in the United States while also adding leading water-purity testing capabilities to our menu. Integrated eight acquisitions completed in 2024, providing the basis for growth in new geographies, including Canada. Expanded and initiated new collaborations to serve in-network providers and members in new geographies. Formed a first-of-its-kind collaboration with Epic to be our technology partner for Project Nova, our multi-year order-to-cash transformation to streamline systems and improve customer experiences, regardless of the electronic health record they use, for smarter, simpler testing. Serving Consumers Further advanced our position as the premier lab engine powering the wellness industry through questhealth.com, our consumer-initiated test platform, and through new collaborations with top consumer wellness and wearables companies. Expanded our offerings on questhealth.com to more than 150 tests, including our new Elite Health Panel for assessing health based on over 85 biomarkers. Delivering Clinical Innovations Added category-defining innovations to our Advanced Diagnostics portfolio, including a new Quest AD-Detect® blood test for aiding the diagnosis of Alzheimer's disease, long-read gene sequencing to identify the cause of ataxia movement disorders, and HPV self-collection options for cervical cancer screening. Secured FDA breakthrough device designation for the Haystack MRD® test for monitoring patients treated for solid-tumor cancers. Formed collaborations with The University of Texas MD Anderson Cancer Center and Rutgers Cancer Institute to research and develop innovations for detecting early signs of cancer. Supported public health with Oropouche virus testing under a preparedness contract with the U.S. Centers for Disease Control and Prevention. Driving Operational Excellence Delivered 3% annual cost savings and productivity improvements through our Invigorate program. Deployed AI and automation across lab, customer and administrative systems, including automated sample processing, logistics and cytology, improving quality, experiences and productivity. Engaged Google Cloud to use generative AI to simplify and improve data management and analytics. Guidance for Full Year 2026 The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page of its investor relations website, which can be found at . Note on Non-GAAP Financial Measures As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items. Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures. Conference Call Information Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at . We suggest participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at or, from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern Time on February 24, 2026, by phone at 866-388-5361 for domestic callers and 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. About Quest Diagnostics Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. Forward Looking Statements The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports. This earnings release, including the attached financial tables, is available online in the Newsroom section at . ADDITIONAL TABLES FOLLOW Notes to Financial Tables SOURCE Quest Diagnostics 21% more press release views with Request a Demo

Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announced that it has signed a contract with the University of Texas MD Anderson Cancer Center, ranked #1 in cancer care by U.S. News & World Report, to re-equip and modernize its existing Proton Therapy Center in Houston with three state-of-the-art Proteus ® ONE 1 systems. IBA was awarded the project following a publicly regulated, competitive RFP-process. This comprehensive retrofit will enhance proton therapy capabilities, streamline operations, and ensure patients continue to benefit from the most advanced and precise proton therapy technology available today. The typical end-user price for one Proteus ® ONE solution, including a multi-year maintenance contract, ranges between USD 45 and 55 million 2 . Olivier Legrain, Chief Executive Officer of IBA, commented : “ Being selected by the world’s leading oncology center is a strong validation of IBA’s technology, innovation roadmap, and long-term commitment to proton therapy. MD Anderson’s mission to eliminate cancer through outstanding clinical care, research, and education is fully aligned with our ambitions. It is a true honor and a strong commitment from IBA to contribute to that mission. With Proteus ® ONE, we are not only delivering today’s state-of-the-art proton therapy technology, but also a future-ready platform designed to integrate upcoming innovations. This will support improved patient care, advanced research activities, and the continued generation of high-quality clinical evidence, helping to make proton therapy available to all patients that could benefit for it. ” MD Anderson recently published the results of a landmark phase 3 clinical trial in The Lancet 3 demonstrating that intensity-modulated proton therapy significantly reduces toxicity while improving overall survival compared to IMRT for patients with advanced oropharyngeal cancer, positioning proton therapy as a new standard of care for this indication (see IBA press release dated 15.12.2025). ***ENDS*** About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be one of the most advanced forms of radiation therapy available today, industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: About MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson provides cancer care at several locations throughout the Greater Houston Area and collaborates with health systems nationwide through MD Anderson Cancer Network®. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation's original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 57 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report's "Best Hospitals" rankings has named MD Anderson the nation's top hospital for cancer care. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990. CONTACTS IBA Thomas Pevenage Investor relations +32 10 475 890 investorrelations@iba-group.com Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com 1 Proteus ® ONE is a brand name of Proteus®235 2 This contract, signed at the end of December, will be booked in IBA’s 2025 order intake. In accordance with its financial communication policy, IBA announces the conclusion of commercial contracts after receiving the first instalment. 3 Frank, Steven JBates, James et al. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial - The Lancet, Volume 407, Issue 10524, 174 – 184 Attachment 260119-IBA-MDAnderson-3ProteusONE_selection-EN

Pfizer’s Braftovi (encorafenib), in combination with Erbitux (cetuximab) and Folfiri (fluorouracil, leucovorin and irinotecan), has shown positive results in a new trial of patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Braftovi is an oral small molecule kinase inhibitor designed to specifically target BRAF V600E. Results from cohort 3 of the BREAKWATER trial showed that the Braftovi-Erbitux-Folfiri combination regimen demonstrated a clinically meaningful and statistically significant response rate in this patient group, compared with patients receiving Folfiri with or without bevacizumab. Within the Braftovi combination treatment arm, 57.4% of patients saw a response lasting six months or longer, compared with 34.5% of patients receiving Folfiri with or without bevacizumab. The Braftovi combination regimen demonstrated a safety profile consistent with each drug’s established safety profile, and no new safety signals were identified by the trial. The BREAKWATER trial is ongoing and is expected to be completed in 2027. CRC is the third most common cancer worldwide and the second leading cause of cancer-related deaths. Around 154,720 people in the US are expected to be diagnosed with CRC in 2025, and around 53,000 people in the US die from the disease annually. Additionally, 20% of all CRC patients see their disease metastasise or spread to other areas of the body. Approximately 8-12% of people with mCRC develop BRAF mutations, with BRAF V600E being the most common. Mortality risk in CRC patients with BRAF V600E mutation is over double that of patients without known mutation. Prior to December 2024 there were no approved biomarker-driven treatments for previously untreated mCRC with BRAF V600E mutations. Scott Kopetz, Professor and Deputy Chair of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center and co-principal investigator of the BREAKWATER trial, said: “These results represent a great advance for patients with BRAF V600E-mutant mCRC. We’ve seen this approach significantly increase the response compared to Folfiri with or without bevacizumab, and these responses were rapid and durable. “The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population.” Jeff Legos, chief oncology officer at Pfizer, added: “These results underscore the potential of Braftovi as a standard of care for patients with this aggressive cancer.” The data will be presented in an oral presentation at the 2026 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium.